Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with DCIS (a type of early, non-invasive breast condition) where imaging tests such as mammography, MRI, or ultrasound suggest the affected area is larger than 4 cm
- People for whom a surgeon has planned to remove the DCIS, either by removing part of the breast or the whole breast, in line with standard medical guidelines
- People who are willing and able to provide written consent to participate
- Women who could become pregnant must have a confirmed recent menstrual period (if applicable) and a negative pregnancy test before joining
- Women who could become pregnant, and men whose partners could become pregnant, must agree to use highly effective contraception during any sexual activity from the time of signing the consent form until the final trial visit
Who may not be able to join:
- People who cannot have an MRI scan — for example, due to certain metal implants in the body, severe claustrophobia, or a history of a severe allergic reaction to MRI contrast dye
- People whose kidneys are not functioning well enough (a specific kidney function measurement below a certain threshold — confirm with trial site)
- People who are currently pregnant, or who have been pregnant within the 8 weeks before starting the study
- People who are currently breastfeeding, or who have breastfed within the 8 weeks before starting the study
- People who are not able to understand what the study involves, including its risks and benefits
- People who have previously been diagnosed with invasive breast cancer on the same side as the current DCIS diagnosis
- People who have also been diagnosed with invasive cancer in the other breast, unless that cancer was treated with curative surgery more than one year ago
- People with a known allergy or sensitivity to the study drug or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philipp Backhaus, Dr. med., Department of Nuclear Medicine, University Hospital Münster
Phone: +4925183
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of feasibility of detection of occult invasive cancer in diagnosed DCIS of [68Ga]Ga-FAPI-46 breast PET/MRI; Evaluation of feasibility of detection of occult invasive cancer in diagnosed DCIS of [68Ga]Ga-FAPI-46 breast PET/MRI
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.